Patents by Inventor Gaddamanugu L. Prasad

Gaddamanugu L. Prasad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for assessing risk of substance administration
    Patent number: 10309956
    Abstract: A process for assessing risk that administration of a substance will suppress immune competence in a population of subjects is provided. Such a substance may be a substance related to, contained in or derived from a tobacco product or, more generally, a substance concerning which it is desired to assess risk of administration of the substance.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: June 4, 2019
    Assignees: R.J. Reynolds Tobacco Company, Wake Forest University Health Sciences
    Inventors: Gaddamanugu L. Prasad, Subhashini Arimilli
  • PROCESS FOR ASSESSING RISK OF SUBSTANCE ADMINISTRATION
    Publication number: 20160025705
    Abstract: A process for assessing risk that administration of a substance will suppress immune competence in a population of subjects is provided. Such a substance may be a substance related to, contained in or derived from a tobacco product or, more generally, a substance concerning which it is desired to assess risk of administration of the substance.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 28, 2016
    Inventors: GADDAMANUGU L. PRASAD, Subhashini Arimilli
  • HME1 nucleic acids and probes
    Patent number: 5776676
    Abstract: A full length cDNA clone from a normal human mammary epithelial cell (strain 184) encoding a 25 kDa protein, HME1, was isolated. Expression of HME1 RNA appears to be limited to epithelial cells. The HME1 sequence shares strong sequence homology with bovine 14-3-3 protein, which is an activator of tyrosine and tryptophan hydroxylase, but the tissue distribution of HME1 differs from that of 14-3-3. Compared with normal mammary epithelial cells, expression of HME1 RNA is dramatically low in cells derived from human mammary carcinoma and in normal mammary epithelial cells transformed by oncogenes. HME1 therefore appears to be a cellular differentiation marker that is down-regulated during neoplastic transformation.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 7, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gaddamanugu L. Prasad, Herbert L. Cooper
  • Epithelial cell specific differentiation marker
    Patent number: 5424191
    Abstract: A full length cDNA clone from a normal human mammary epithelial cell (strain 184) encoding a 25 kDa protein, HME1, was isolated. Expression of HME1 RNA appears to be limited to epithelial cells. The HME1 sequence shares strong sequence homology with bovine 14-3-3 protein, which is an activator of tyrosine and tryptophan hydroxylase, but the tissue distribution of HME1 differs from that of 14-3-3. Compared with normal mammary epithelial cells, expression of HME1 RNA is dramatically low in cells derived from human mammary carcinoma and in normal mammary epithelial cells transformed by oncogenes. HME1 therefore appears to be a cellular differentiation marker that is down-regulated during neoplastic transformation.
    Type: Grant
    Filed: May 20, 1992
    Date of Patent: June 13, 1995
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gaddamanugu L. Prasad, Herbert L. Cooper